Kamada Secures $50 Million Plasma Supply Agreement
Kamada Ltd. has entered into a new three-year agreement to supply normal source plasma from its collection centers in Texas, a deal expected to generate approximately $50 million in revenue.
Strategic Impact of the Texas Plasma Collection Centers
The Role of Plasma-Derived Therapeutics in Market Growth
Frequently Asked Questions
What is the duration of the new Kamada plasma agreement? The agreement is set for a three-year term, covering the supply of normal source plasma from the company’s Texas-based collection centers.
What is the expected financial impact of the deal? Kamada anticipates that the agreement will generate approximately $50 million in total revenue over the three-year period.
Why does Kamada operate its own plasma collection centers?
***
Are you interested in the latest developments in the biopharmaceutical sector? Subscribe to our industry newsletter for weekly updates on market trends, M&A activity, and clinical trial breakthroughs.
Related reading